SPRY

ARS Pharmaceuticals, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$3.81

Price (1 Year)

$13.06 $2.79

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %12.3 / %30
Non-compliant assets / Total market cap %13.9 / %30
Non-compliant revenue / Total income %5 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.

Website

Analysis (Turkish): SPRY Hissesi Caiz mi, Helal mi? ARS Pharmaceuticals, Inc. Katılım Analizi